Gilead Sciences (NASDAQ:GILD)‘s stock had its “buy” rating reissued by equities research analysts at JPMorgan Chase & Co. in a research note issued to investors on Thursday.
Other analysts have also recently issued research reports about the company. ValuEngine cut Gilead Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, February 13th. Oppenheimer upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $85.00 target price for the company in a report on Thursday, January 3rd. CIBC upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $85.00 target price for the company in a report on Thursday, January 3rd. Wells Fargo & Co decreased their target price on Gilead Sciences from $95.00 to $89.00 and set an “outperform” rating for the company in a report on Tuesday, February 5th. Finally, Zacks Investment Research cut Gilead Sciences from a “buy” rating to a “hold” rating in a report on Monday, December 31st. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $82.56.
Get Gilead Sciences alerts:Gilead Sciences stock opened at $62.92 on Thursday. The stock has a market cap of $85.04 billion, a P/E ratio of 10.23, a P/E/G ratio of 4.14 and a beta of 1.19. Gilead Sciences has a 52 week low of $60.32 and a 52 week high of $82.71. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.36 and a quick ratio of 3.29.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 EPS for the quarter, missing the consensus estimate of $1.70 by ($0.26). The business had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.52 billion. Gilead Sciences had a net margin of 24.65% and a return on equity of 37.03%. The firm’s quarterly revenue was down 2.6% compared to the same quarter last year. During the same quarter last year, the firm earned $1.78 EPS. As a group, sell-side analysts forecast that Gilead Sciences will post 6.23 earnings per share for the current year.
In related news, Director Gayle E. Wilson sold 19,068 shares of the business’s stock in a transaction that occurred on Tuesday, February 19th. The stock was sold at an average price of $67.08, for a total transaction of $1,279,081.44. Following the transaction, the director now directly owns 143,567 shares of the company’s stock, valued at approximately $9,630,474.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.16% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the stock. Athena Capital Advisors LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at approximately $27,000. Capital Financial Planning LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at approximately $27,000. Advisors Preferred LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at approximately $31,000. Legacy Financial Advisors Inc. raised its position in shares of Gilead Sciences by 361.3% in the 4th quarter. Legacy Financial Advisors Inc. now owns 489 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 383 shares in the last quarter. Finally, Claybrook Capital LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at approximately $32,000. 77.76% of the stock is currently owned by hedge funds and other institutional investors.
About Gilead Sciences
Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Further Reading: Current Ratio
No comments:
Post a Comment